Vaccines, Clinical Advancement, and Associated Immunology
A section of Vaccines (ISSN 2076-393X).
Section Information
Aims
The aim of the Section “Vaccines, Clinical Advancement, and Associated Immunology” is to highlight advances in vaccines and the associated immunology, vaccine clinical advancement, and vaccine-induced immunological changes, including immune-based adverse events induced by vaccines. This Section will provide a forum for novel insights into immunological mechanisms, translational applications, and the development of new vaccines.
Scope
We welcome articles focusing on the immunology of vaccines for infectious diseases, the design and development of new vaccines, and the clinical aspects of vaccinations, including adverse events and clinical entities that may occur following prophylactic and therapeutic vaccination. We also welcome submissions addressing preclinical and clinical studies related to vaccination in patients with immune-mediated disorders. The Section encourages translational research bridging experimental findings with human applications, and will consider original research articles, brief reports, reviews, and others relevant article types.
Keywords
- clinical immunology
- immune-mediated diseases
- vaccine adverse events
- vaccine immunopathology
Editorial Board
Topical Advisory Panel
Special Issues
Following special issues within this section are currently open for submissions:
- Neurobiological Impacts of Infection, Protective Effects, and Clinical Implications of Vaccines (Deadline: 30 September 2026)
- Novel Immunotherapeutic Strategies Targeting Autoimmune and Inflammatory Diseases (Deadline: 31 October 2026)
- Herpes Simplex Virus Infection, Immunity, and Vaccine Development (Deadline: 31 December 2026)
- Human Immune Responses to Infection and Vaccination: 2nd Edition (Deadline: 31 December 2026)
- Immune Responses in Patients with Chronic Disease After Vaccination (Deadline: 31 January 2027)
- Antibodies in Autoimmune, Chronic, and Infectious Diseases: Pathogenic Mechanisms, Biomarkers, and Vaccine Development (Deadline: 31 January 2027)
- Genetically Engineered Mouse Models in Vaccine Development (Deadline: 31 January 2027)
- Respiratory Virus Vaccines: Mechanisms of Durable Immunity and Innovation (Deadline: 31 January 2027)
- Skin Inflammation and Immunology: Vaccines, Immunomodulation, and Translational Therapeutics (Deadline: 31 May 2027)
- Immunogenicity, Safety, and Coverage of Vaccines in Patients with Autoimmune Diseases (Deadline: 31 July 2027)
